Loading asset research
Trevi Therapeutics Inc. Common Stock
TRVINasdaq · USD · StocksQuote as of · Exchange session not verified$15.92
+0.06%
Today
TRVI
Loading 1D prices…
Market cap
$2.3B
Volume
2M
52w high
$20.2252w low
$7.64Company profile
Trevi Therapeutics Inc. Common Stock
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New Haven, CT, United States
Employees
34
Fiscal year end
1231
CIK
1563880
Session & valuation
Open$16.20
Previous close$15.91
Day high$16.57
Day low$15.87
30-day avg. volume1.5M
Outstanding shares142.5M
Diluted EPS-$0.32
Latest annual period
P/E (trailing)-49.75
P/E (forward)-27.56
Price / book7.04
Beta1.05
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| HCMHUTCHMED (China) Limited American Depositary Shares | $2.2B | $548.5M | +83.30% | $0.52 | -2.29% | Hold |
| OCULOcular Therapeutix Inc. Common Stock | $2.3B | $52M | -511.90% | -$1.42 | -1.18% | Buy |
| PBHPrestige Consumer Healthcare Inc. Common Stock | $2.2B | $1.1B | +17.48% | $3.91 | -0.82% | Hold |
| SLSSELLAS Life Sciences Group Inc. Common Stock | $2.3B | $0.00 | — | -$0.25 | -14.42% | Buy |
| BHCBausch Health Companies Inc. Common Stock | $2.2B | $10.3B | +1.53% | $0.42 | -3.46% | Hold |